Drug Profile

FIN 525

Alternative Names: FIN-525

Latest Information Update: 29 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Finch Therapeutics Group
Developer Finch Therapeutics Group; Takeda
Class Anti-inflammatories; Bacteria; Probiotics
Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

25 Aug 2022 FIN 525 is available for licensing as of 25 Aug 2022.
25 Aug 2022 Finch therapeutics to regain full development and commercial rights to FIN 525 from November 17, 2022
25 Aug 2022 Preclinical trials in Crohn's disease in USA before August 2022 (PO)(Finch Therapeutics pipeline - August 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com